SK7612002A3 - Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus - Google Patents
Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus Download PDFInfo
- Publication number
- SK7612002A3 SK7612002A3 SK761-2002A SK7612002A SK7612002A3 SK 7612002 A3 SK7612002 A3 SK 7612002A3 SK 7612002 A SK7612002 A SK 7612002A SK 7612002 A3 SK7612002 A3 SK 7612002A3
- Authority
- SK
- Slovakia
- Prior art keywords
- dna
- virus
- infectious
- rna
- coronavirus
- Prior art date
Links
- 150000007523 nucleic acids Chemical group 0.000 title claims abstract description 51
- 230000015572 biosynthetic process Effects 0.000 title description 4
- 210000004507 artificial chromosome Anatomy 0.000 title 1
- 108020004414 DNA Proteins 0.000 claims abstract description 118
- 241000700605 Viruses Species 0.000 claims abstract description 102
- 241000711573 Coronaviridae Species 0.000 claims abstract description 96
- 238000000034 method Methods 0.000 claims abstract description 84
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 60
- 210000002845 virion Anatomy 0.000 claims abstract description 58
- 210000004436 artificial bacterial chromosome Anatomy 0.000 claims abstract description 50
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 43
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 43
- 108020000999 Viral RNA Proteins 0.000 claims abstract description 33
- 239000012634 fragment Substances 0.000 claims abstract description 32
- 241001493065 dsRNA viruses Species 0.000 claims abstract description 19
- 101710172711 Structural protein Proteins 0.000 claims abstract description 18
- 108060004795 Methyltransferase Proteins 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 105
- 208000015181 infectious disease Diseases 0.000 claims description 98
- 210000004027 cell Anatomy 0.000 claims description 97
- 230000002458 infectious effect Effects 0.000 claims description 84
- 241000711484 Transmissible gastroenteritis virus Species 0.000 claims description 65
- 239000012678 infectious agent Substances 0.000 claims description 64
- 239000013612 plasmid Substances 0.000 claims description 59
- 239000013598 vector Substances 0.000 claims description 56
- 230000014509 gene expression Effects 0.000 claims description 51
- 229960005486 vaccine Drugs 0.000 claims description 43
- 239000013603 viral vector Substances 0.000 claims description 43
- 239000000427 antigen Substances 0.000 claims description 34
- 108091007433 antigens Proteins 0.000 claims description 34
- 102000036639 antigens Human genes 0.000 claims description 34
- 230000028993 immune response Effects 0.000 claims description 27
- 241001465754 Metazoa Species 0.000 claims description 24
- 230000001939 inductive effect Effects 0.000 claims description 22
- 230000010076 replication Effects 0.000 claims description 21
- 238000013518 transcription Methods 0.000 claims description 21
- 230000035897 transcription Effects 0.000 claims description 21
- 230000010415 tropism Effects 0.000 claims description 20
- 101150010882 S gene Proteins 0.000 claims description 19
- 239000002773 nucleotide Substances 0.000 claims description 19
- 241000894006 Bacteria Species 0.000 claims description 18
- 238000012217 deletion Methods 0.000 claims description 18
- 230000037430 deletion Effects 0.000 claims description 18
- 125000003729 nucleotide group Chemical group 0.000 claims description 18
- 230000003612 virological effect Effects 0.000 claims description 18
- 241000701022 Cytomegalovirus Species 0.000 claims description 15
- 108010006025 bovine growth hormone Proteins 0.000 claims description 14
- 230000002950 deficient Effects 0.000 claims description 13
- 241000282324 Felis Species 0.000 claims description 12
- 241000282414 Homo sapiens Species 0.000 claims description 12
- 238000010367 cloning Methods 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 231100000331 toxic Toxicity 0.000 claims description 12
- 230000002588 toxic effect Effects 0.000 claims description 12
- 108020004635 Complementary DNA Proteins 0.000 claims description 11
- 238000003780 insertion Methods 0.000 claims description 11
- 230000002452 interceptive effect Effects 0.000 claims description 11
- 238000001890 transfection Methods 0.000 claims description 11
- 241000588724 Escherichia coli Species 0.000 claims description 10
- 108091034057 RNA (poly(A)) Proteins 0.000 claims description 10
- 239000012528 membrane Substances 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 230000002238 attenuated effect Effects 0.000 claims description 9
- 230000000968 intestinal effect Effects 0.000 claims description 9
- 210000004379 membrane Anatomy 0.000 claims description 9
- 229940031348 multivalent vaccine Drugs 0.000 claims description 9
- 230000008488 polyadenylation Effects 0.000 claims description 9
- 102000053642 Catalytic RNA Human genes 0.000 claims description 8
- 108090000994 Catalytic RNA Proteins 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 8
- 230000000241 respiratory effect Effects 0.000 claims description 8
- 108091092562 ribozyme Proteins 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- 208000005577 Gastroenteritis Diseases 0.000 claims description 7
- 241000711466 Murine hepatitis virus Species 0.000 claims description 7
- 238000001415 gene therapy Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 241000711443 Bovine coronavirus Species 0.000 claims description 6
- 208000037262 Hepatitis delta Diseases 0.000 claims description 6
- 241000282412 Homo Species 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 208000029570 hepatitis D virus infection Diseases 0.000 claims description 6
- 241000711450 Infectious bronchitis virus Species 0.000 claims description 5
- 230000001276 controlling effect Effects 0.000 claims description 5
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 244000309467 Human Coronavirus Species 0.000 claims description 4
- 238000007792 addition Methods 0.000 claims description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- 239000003124 biologic agent Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000003623 enhancer Substances 0.000 claims description 4
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims description 4
- 230000003362 replicative effect Effects 0.000 claims description 4
- 210000002345 respiratory system Anatomy 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 241000709664 Picornaviridae Species 0.000 claims description 3
- 241000711517 Torovirus Species 0.000 claims description 3
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 210000004400 mucous membrane Anatomy 0.000 claims description 3
- 241001115070 Bornavirus Species 0.000 claims description 2
- 241000711506 Canine coronavirus Species 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 2
- 241000711950 Filoviridae Species 0.000 claims description 2
- 241000710831 Flavivirus Species 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000010804 cDNA synthesis Methods 0.000 claims 8
- 239000002299 complementary DNA Substances 0.000 claims 8
- 241000724709 Hepatitis delta virus Species 0.000 claims 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000013519 translation Methods 0.000 claims 1
- 230000009452 underexpressoin Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 description 16
- 238000010276 construction Methods 0.000 description 13
- 241000282465 Canis Species 0.000 description 10
- 230000037431 insertion Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 108091027544 Subgenomic mRNA Proteins 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 241000282326 Felis catus Species 0.000 description 7
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 241000710961 Semliki Forest virus Species 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 5
- 241000282887 Suidae Species 0.000 description 5
- 241000282898 Sus scrofa Species 0.000 description 5
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 5
- 229960005091 chloramphenicol Drugs 0.000 description 5
- 230000000120 cytopathologic effect Effects 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 108091080980 Hepatitis delta virus ribozyme Proteins 0.000 description 4
- 241000702263 Reovirus sp. Species 0.000 description 4
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 241000710929 Alphavirus Species 0.000 description 3
- 101100328086 Caenorhabditis elegans cla-1 gene Proteins 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 3
- 102100031673 Corneodesmosin Human genes 0.000 description 3
- 101710139375 Corneodesmosin Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 241000711798 Rabies lyssavirus Species 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- 108020005065 3' Flanking Region Proteins 0.000 description 2
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108010041052 DNA Topoisomerase IV Proteins 0.000 description 2
- 241000450599 DNA viruses Species 0.000 description 2
- 101100278012 Escherichia coli (strain K12) dnaG gene Proteins 0.000 description 2
- 241001302160 Escherichia coli str. K-12 substr. DH10B Species 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 description 2
- 230000006819 RNA synthesis Effects 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 101100165173 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) basS gene Proteins 0.000 description 2
- 241000710960 Sindbis virus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 101100421924 Thermus thermophilus (strain ATCC BAA-163 / DSM 7039 / HB27) spo0C gene Proteins 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 229940028617 conventional vaccine Drugs 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 101150004979 flmA gene Proteins 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 229940037201 oris Drugs 0.000 description 2
- 101150048892 parB gene Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 101150034434 repE gene Proteins 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- LHEJDBBHZGISGW-UHFFFAOYSA-N 5-fluoro-3-(3-oxo-1h-2-benzofuran-1-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(F)=CNC(=O)N1C1C2=CC=CC=C2C(=O)O1 LHEJDBBHZGISGW-UHFFFAOYSA-N 0.000 description 1
- 101710082414 50S ribosomal protein L12, chloroplastic Proteins 0.000 description 1
- 101000621943 Acholeplasma phage L2 Probable integrase/recombinase Proteins 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 101000618348 Allochromatium vinosum (strain ATCC 17899 / DSM 180 / NBRC 103801 / NCIMB 10441 / D) Uncharacterized protein Alvin_0065 Proteins 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 241001533362 Astroviridae Species 0.000 description 1
- 201000008283 Atrophic Rhinitis Diseases 0.000 description 1
- 101000781117 Autographa californica nuclear polyhedrosis virus Uncharacterized 12.4 kDa protein in CTL-LEF2 intergenic region Proteins 0.000 description 1
- 101000708323 Azospirillum brasilense Uncharacterized 28.8 kDa protein in nifR3-like 5'region Proteins 0.000 description 1
- 101000770311 Azotobacter chroococcum mcd 1 Uncharacterized 19.8 kDa protein in nifW 5'region Proteins 0.000 description 1
- 101000748761 Bacillus subtilis (strain 168) Uncharacterized MFS-type transporter YcxA Proteins 0.000 description 1
- 101000765620 Bacillus subtilis (strain 168) Uncharacterized protein YlxP Proteins 0.000 description 1
- 101000916134 Bacillus subtilis (strain 168) Uncharacterized protein YqxJ Proteins 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 101000754349 Bordetella pertussis (strain Tohama I / ATCC BAA-589 / NCTC 13251) UPF0065 protein BP0148 Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001148534 Brachyspira Species 0.000 description 1
- 241000724268 Bromovirus Species 0.000 description 1
- 101000827633 Caldicellulosiruptor sp. (strain Rt8B.4) Uncharacterized 23.9 kDa protein in xynA 3'region Proteins 0.000 description 1
- 241000680578 Canid alphaherpesvirus 1 Species 0.000 description 1
- 241001279357 Canine calicivirus Species 0.000 description 1
- 241000701157 Canine mastadenovirus A Species 0.000 description 1
- 241000712083 Canine morbillivirus Species 0.000 description 1
- 241001353878 Canine parainfluenza virus Species 0.000 description 1
- 241000701931 Canine parvovirus Species 0.000 description 1
- 241001493036 Canine rotavirus Species 0.000 description 1
- 241001647378 Chlamydia psittaci Species 0.000 description 1
- 241000710777 Classical swine fever virus Species 0.000 description 1
- 101000947628 Claviceps purpurea Uncharacterized 11.8 kDa protein Proteins 0.000 description 1
- 101000686796 Clostridium perfringens Replication protein Proteins 0.000 description 1
- 241000193464 Clostridium sp. Species 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 description 1
- 101150097493 D gene Proteins 0.000 description 1
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 1
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 101000788129 Escherichia coli Uncharacterized protein in sul1 3'region Proteins 0.000 description 1
- 101000788370 Escherichia phage P2 Uncharacterized 12.9 kDa protein in GpA 3'region Proteins 0.000 description 1
- 241000701087 Felid alphaherpesvirus 1 Species 0.000 description 1
- 241000714201 Feline calicivirus Species 0.000 description 1
- 241000725579 Feline coronavirus Species 0.000 description 1
- 241000713800 Feline immunodeficiency virus Species 0.000 description 1
- 241000711475 Feline infectious peritonitis virus Species 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 241000701915 Feline panleukopenia virus Species 0.000 description 1
- 101000787096 Geobacillus stearothermophilus Uncharacterized protein in gldA 3'region Proteins 0.000 description 1
- 241000606807 Glaesserella parasuis Species 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 101000976889 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 19.2 kDa protein in cox-rep intergenic region Proteins 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 241000617996 Human rotavirus Species 0.000 description 1
- 101710126256 Hydrolase in agr operon Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 101000827627 Klebsiella pneumoniae Putative low molecular weight protein-tyrosine-phosphatase Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 101001130841 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF5 Proteins 0.000 description 1
- 101100107522 Mus musculus Slc1a5 gene Proteins 0.000 description 1
- 241000204045 Mycoplasma hyopneumoniae Species 0.000 description 1
- 241001644525 Nastus productus Species 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 101150001779 ORF1a gene Proteins 0.000 description 1
- 241000713112 Orthobunyavirus Species 0.000 description 1
- 241000209094 Oryza Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000710778 Pestivirus Species 0.000 description 1
- 241000702619 Porcine parvovirus Species 0.000 description 1
- 241000711493 Porcine respiratory coronavirus Species 0.000 description 1
- 241000702665 Porcine rotavirus Species 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 206010039088 Rhinitis atrophic Diseases 0.000 description 1
- 101000974028 Rhizobium leguminosarum bv. viciae (strain 3841) Putative cystathionine beta-lyase Proteins 0.000 description 1
- 101000756519 Rhodobacter capsulatus (strain ATCC BAA-309 / NBRC 16581 / SB1003) Uncharacterized protein RCAP_rcc00048 Proteins 0.000 description 1
- 101000948219 Rhodococcus erythropolis Uncharacterized 11.5 kDa protein in thcD 3'region Proteins 0.000 description 1
- 241000711897 Rinderpest morbillivirus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 101150027674 S1 gene Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 101000936711 Streptococcus gordonii Accessory secretory protein Asp4 Proteins 0.000 description 1
- 101000929863 Streptomyces cinnamonensis Monensin polyketide synthase putative ketoacyl reductase Proteins 0.000 description 1
- 101000788468 Streptomyces coelicolor Uncharacterized protein in mprR 3'region Proteins 0.000 description 1
- 101000845085 Streptomyces violaceoruber Granaticin polyketide synthase putative ketoacyl reductase 1 Proteins 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 101000711771 Thiocystis violacea Uncharacterized 76.5 kDa protein in phbC 3'region Proteins 0.000 description 1
- 101000711318 Vibrio alginolyticus Uncharacterized 11.6 kDa protein in scrR 3'region Proteins 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002223 anti-pathogen Effects 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 108091092330 cytoplasmic RNA Proteins 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 108010028403 hemagglutinin esterase Proteins 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000001983 lactogenic effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000114864 ssRNA viruses Species 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
- A61K39/225—Porcine transmissible gastroenteritis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20041—Use of virus, viral particle or viral elements as a vector
- C12N2770/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20061—Methods of inactivation or attenuation
- C12N2770/20062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES009902673A ES2170622B1 (es) | 1999-12-03 | 1999-12-03 | Clones y vectores infectivos derivados de coronavirus y sus aplicaciones. |
PCT/EP2000/012063 WO2001039797A2 (en) | 1999-12-03 | 2000-11-30 | Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus |
Publications (1)
Publication Number | Publication Date |
---|---|
SK7612002A3 true SK7612002A3 (en) | 2002-11-06 |
Family
ID=8310818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK761-2002A SK7612002A3 (en) | 1999-12-03 | 2000-11-30 | Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus |
Country Status (27)
Country | Link |
---|---|
US (4) | US7445928B2 (pl) |
EP (2) | EP1234024B2 (pl) |
JP (1) | JP4637432B2 (pl) |
KR (1) | KR100755814B1 (pl) |
CN (3) | CN1872994A (pl) |
AR (1) | AR027893A1 (pl) |
AT (1) | ATE267246T1 (pl) |
AU (2) | AU785081B2 (pl) |
BR (1) | BR0016145A (pl) |
CA (1) | CA2393325A1 (pl) |
CZ (1) | CZ302785B6 (pl) |
DE (1) | DE60010921T3 (pl) |
DK (1) | DK1234024T4 (pl) |
ES (2) | ES2170622B1 (pl) |
HU (1) | HU228205B1 (pl) |
IL (2) | IL149859A0 (pl) |
MX (1) | MXPA02005525A (pl) |
NO (1) | NO331812B1 (pl) |
NZ (1) | NZ518990A (pl) |
PL (1) | PL206816B1 (pl) |
PT (1) | PT1234024E (pl) |
RS (1) | RS50372B (pl) |
SI (1) | SI1234024T2 (pl) |
SK (1) | SK7612002A3 (pl) |
TR (1) | TR200401186T4 (pl) |
WO (1) | WO2001039797A2 (pl) |
ZA (1) | ZA200203560B (pl) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2170622B1 (es) | 1999-12-03 | 2004-05-16 | Consejo Superior De Investigaciones Cientificas | Clones y vectores infectivos derivados de coronavirus y sus aplicaciones. |
AU2002311668B2 (en) * | 2001-05-17 | 2007-10-04 | Stichting Voor De Technische Wetenschappen | Corona-virus-like particles comprising functionally deleted genomes |
US7556957B2 (en) | 2001-05-17 | 2009-07-07 | Stichting Voor De Technische Wetenschappen | Coronavirus-like particles comprising functionally deleted genomes |
US7906311B2 (en) | 2002-03-20 | 2011-03-15 | Merial Limited | Cotton rat lung cells for virus culture |
US7371837B2 (en) * | 2004-07-21 | 2008-05-13 | The University Of Hong Kong | Human virus causing respiratory tract infection and uses thereof |
EP1619246A1 (en) * | 2004-07-23 | 2006-01-25 | Université de la Méditerranée, Aix-Marseille II | RNA dependent RNA polymerases from coronavirus and their use in molecular biology and drug screening |
CA2591532A1 (en) * | 2004-09-03 | 2006-03-09 | Consejo Superior De Investigaciones Cientificas | Nucleic acid sequences encoding proteins capable of associating into a virus-like particle |
EP1632247A1 (en) * | 2004-09-03 | 2006-03-08 | Consejo Superior De Investigaciones Cientificas | Nucleic acid sequences encoding FMDV proteins capable of associating into a virus-like particle |
US20060130157A1 (en) | 2004-10-22 | 2006-06-15 | Kevin Wells | Ungulates with genetically modified immune systems |
EP1792996A1 (en) | 2005-12-01 | 2007-06-06 | Consejo Superior de Investigaciones Cientificas | Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV) |
JP2007312649A (ja) * | 2006-05-24 | 2007-12-06 | Japan Health Science Foundation | 再構築された感染性レトロウイルスゲノムクローンdna及びそれを含む微生物ならびにそれらの製造方法 |
ES2548377T3 (es) | 2008-10-27 | 2015-10-16 | Revivicor, Inc. | Ungulados inmunodeprimidos |
FR2947839A1 (fr) * | 2009-07-09 | 2011-01-14 | Centre Nat Rech Scient | Nouveaux agents antibacteriens |
US9597390B2 (en) | 2011-03-02 | 2017-03-21 | Utrech University | Infectious bronchitis virus (IBV) spike protein as subunit vaccine |
GB201307528D0 (en) | 2013-04-26 | 2013-06-12 | Univ Leuven Kath | Bacterial artificial chromosomes |
AU2015259472A1 (en) * | 2014-05-16 | 2016-11-10 | Yale University | Evolution of high-titer virus-like vesicles for vaccine applications |
EP3143144A4 (en) * | 2014-05-16 | 2017-12-20 | Yale University | VIRUS LIKE VESICLES (VLVs) BASED VACCINES TO PREVENT OR TREAT CHRONIC HEPATITIS B VIRUS (HBV) INFECTION |
EP3198008B1 (en) | 2014-09-22 | 2019-05-29 | Regents of the University of Minnesota | Pichinde virus reverse genetics system and methods of use |
GB201603374D0 (en) | 2016-02-26 | 2016-04-13 | Ucl Business Plc | Packaging cell |
CN107190022B (zh) * | 2017-06-28 | 2020-10-30 | 浙江大学 | 一种快速构建禽传染性支气管炎病毒反向遗传株的方法 |
WO2019204654A1 (en) * | 2018-04-18 | 2019-10-24 | Utah State University | Compositions and methods for zika virus characterization and vaccine development |
KR102119875B1 (ko) * | 2019-03-19 | 2020-06-05 | 한국화학연구원 | 한국형 중동호흡기증후군 코로나바이러스 감염성 변이 유전자 및 이의 용도 |
CN110468113A (zh) * | 2019-08-07 | 2019-11-19 | 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) | 重组修饰的猪传染性胃肠炎病毒强毒株及其应用 |
CN110656120A (zh) * | 2019-10-16 | 2020-01-07 | 中国医学科学院医学生物学研究所 | 一种乙脑病毒sa14-14-2的克隆方法及应用 |
CN111662885A (zh) * | 2020-06-22 | 2020-09-15 | 扬州大学 | 两株基因组高度同源猪繁殖与呼吸综合征病毒强弱毒株感染性克隆构建、拯救与应用 |
CN112852873B (zh) * | 2021-02-04 | 2023-03-24 | 华中农业大学 | 一种猪δ冠状病毒感染性克隆质粒的构建方法 |
CN115094142B (zh) * | 2022-07-19 | 2024-05-28 | 中国医学科学院肿瘤医院 | 用于诊断肺肠型腺癌的甲基化标志物 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5833975A (en) * | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
US5288641A (en) | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
US5545412A (en) * | 1985-01-07 | 1996-08-13 | Syntex (U.S.A.) Inc. | N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor |
US4946787A (en) * | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5106733A (en) * | 1987-06-25 | 1992-04-21 | Immunex Corporation | Bovine granulocyte-macrophage colony stimulating factor |
CA2045129A1 (en) | 1989-02-01 | 1990-08-02 | Alfred I. Geller | Herpes simplex virus type i expression vector |
US5811103A (en) * | 1989-03-19 | 1998-09-22 | Akzo Nobel N.V. | Hog cholera virus vaccine and diagnostic |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
CA2039921A1 (en) | 1990-04-16 | 1991-10-17 | Xandra O. Breakefield | Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication |
US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
KR100242671B1 (ko) * | 1991-03-07 | 2000-03-02 | 고돈 에릭 | 유전학적으로 처리한 백신 균주 |
ES2026827A6 (es) * | 1991-03-26 | 1992-05-01 | Ercros Sa | Procedimiento para la produccion de una vacuna subunidad contra el parvovirus porcino. |
US5382425A (en) * | 1992-01-13 | 1995-01-17 | Syntro Corporation | Recombinant swinepox virus |
US6033904A (en) * | 1992-01-13 | 2000-03-07 | Syntro Corporation | Recombinant swinepox virus |
US5658724A (en) | 1992-07-31 | 1997-08-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use |
AU681874B2 (en) * | 1993-02-08 | 1997-09-11 | Bayer Corporation | Process for growing porcine reproductive and respiratory syndrome virus and its use in vaccines |
DE69434447T2 (de) * | 1993-06-07 | 2006-05-18 | Vical, Inc., San Diego | Für die gentherapie verwendbare plasmide |
US20020146392A1 (en) | 1993-06-24 | 2002-10-10 | Frank L. Graham | Helper dependent adenovirus vectors based on site-specific recombinases |
WO1995003400A1 (en) * | 1993-07-23 | 1995-02-02 | Johns Hopkins University School Of Medicine | Recombinationally targeted cloning in yeast artificial chromosomes |
US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
EP0804249A2 (en) * | 1994-03-15 | 1997-11-05 | Brown University Research Foundation | Polymeric gene delivery system |
CA2188447C (en) * | 1994-04-29 | 2002-10-22 | Falko-Gunter Falkner | Recombinant poxviruses with foreign polynucleotides in essential regions |
DK53595A (da) * | 1994-05-13 | 1995-11-14 | Iberica Cyanamid | Rekombinante PRRSV-proteiner, diagnostiske kits og vaccine indeholdende sådanne rekombinante PRRSV-proteiner |
US5585096A (en) | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
WO1996015779A1 (en) | 1994-11-21 | 1996-05-30 | The Trustees Of Columbia University In The City Of New York | Unique associated kaposi's sarcoma virus sequences and uses thereof |
US5719131A (en) * | 1994-12-09 | 1998-02-17 | Genzyme Corporation | Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules |
CA2211743A1 (en) | 1995-02-21 | 1996-08-29 | Cantab Pharmaceuticals Research Limited | Viral preparations, vectors, immunogens, and vaccines |
US6043232A (en) * | 1997-07-23 | 2000-03-28 | Nitromed, Inc. | Nitroso esters of beta-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs |
US5705385A (en) * | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US6019980A (en) * | 1995-06-07 | 2000-02-01 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
US5820869A (en) * | 1995-06-07 | 1998-10-13 | American Home Products Corporation | Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection |
US5851826A (en) | 1995-07-26 | 1998-12-22 | Children's Medical Center Corporation | Helper virus-free herpesvirus vector packaging system |
US5795872A (en) * | 1995-09-19 | 1998-08-18 | Pharmadigm, Inc. | DNA construct for immunization |
US6133243A (en) | 1996-02-22 | 2000-10-17 | Onyx Pharmaceuticals, Inc. | Liposomal-viral DNA complexes for treating disease |
ES2109189B1 (es) | 1996-03-14 | 1998-05-16 | Iberica Cyanamid | Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas. |
FR2751224B1 (fr) * | 1996-07-19 | 1998-11-20 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs |
US6004777A (en) * | 1997-03-12 | 1999-12-21 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
US5990091A (en) * | 1997-03-12 | 1999-11-23 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
DE19733364A1 (de) * | 1997-08-01 | 1999-02-04 | Koszinowski Ulrich H Prof | Verfahren zur Klonierung eines großen Virusgenoms |
US6517843B1 (en) * | 1999-08-31 | 2003-02-11 | Merial | Reduction of porcine circovirus-2 viral load with inactivated PCV-2 |
UA78180C2 (uk) * | 1997-10-03 | 2007-03-15 | Меріаль | Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти |
US6391314B1 (en) * | 1997-10-03 | 2002-05-21 | Merial | Porcine circoviruses vaccines diagnostic reagents |
FR2781159B1 (fr) * | 1998-07-06 | 2000-10-06 | Merial Sas | Vaccin circovirus et parvovirus porcin |
US7211379B2 (en) * | 1997-10-03 | 2007-05-01 | Merial Sas | Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2 |
US6165493A (en) * | 1997-10-22 | 2000-12-26 | New York Blood Center, Inc. | "Methods and compositions for decreasing the frequency of HIV, herpesvirus and sexually transmitted bacterial infections" |
FR2772047B1 (fr) * | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection |
US20040062775A1 (en) * | 1997-12-05 | 2004-04-01 | Agence Francaise De Securite Sanitaire Des Aliments | Circovirus sequences associated with piglet weight loss disease (PWD) |
EP1037909B1 (en) * | 1997-12-11 | 2007-06-13 | University of Saskatchewan | Postweaning multisystemic wasting syndrome virus from pigs |
US6277621B1 (en) * | 1998-02-26 | 2001-08-21 | Medigene, Inc. | Artificial chromosome constructs containing foreign nucleic acid sequences |
US6287856B1 (en) * | 1998-03-13 | 2001-09-11 | University Of Georgia Research Foundation, Inc. | Vaccines against circovirus infections |
US6497883B1 (en) * | 1999-06-10 | 2002-12-24 | Merial | Porcine circovirus recombinant poxvirus vaccine |
ES2170622B1 (es) | 1999-12-03 | 2004-05-16 | Consejo Superior De Investigaciones Cientificas | Clones y vectores infectivos derivados de coronavirus y sus aplicaciones. |
EP1852511B1 (en) | 1999-12-14 | 2010-02-17 | Novartis AG | Bovine immunodeficiency virus (biv) based vectors |
AU2001264802A1 (en) | 2000-05-21 | 2001-12-03 | University Of North Carolina At Chapel Hill | Assembly of large viral genomes and chromosomes from subclones |
DE10044648A1 (de) * | 2000-09-08 | 2002-03-21 | Aventis Behring Gmbh | Verfahren zur Vermehrung oder zur Entfernung von Cirocoviren aus biologischem Material |
PL202951B1 (pl) * | 2001-03-27 | 2009-08-31 | Univ Saskatchewan | Sposoby hodowli wirusów rodzaju cirkowirus |
-
1999
- 1999-12-03 ES ES009902673A patent/ES2170622B1/es not_active Expired - Fee Related
-
2000
- 2000-11-30 NZ NZ518990A patent/NZ518990A/en not_active IP Right Cessation
- 2000-11-30 CN CNA2006100733455A patent/CN1872994A/zh active Pending
- 2000-11-30 CN CNA2004100789786A patent/CN1616670A/zh active Pending
- 2000-11-30 CN CNB008165904A patent/CN100402643C/zh not_active Expired - Fee Related
- 2000-11-30 MX MXPA02005525A patent/MXPA02005525A/es active IP Right Grant
- 2000-11-30 SK SK761-2002A patent/SK7612002A3/sk unknown
- 2000-11-30 DK DK00990628.0T patent/DK1234024T4/da active
- 2000-11-30 CA CA002393325A patent/CA2393325A1/en not_active Abandoned
- 2000-11-30 CZ CZ20021882A patent/CZ302785B6/cs not_active IP Right Cessation
- 2000-11-30 US US10/148,669 patent/US7445928B2/en not_active Expired - Fee Related
- 2000-11-30 EP EP00990628A patent/EP1234024B2/en not_active Expired - Lifetime
- 2000-11-30 AU AU30051/01A patent/AU785081B2/en not_active Ceased
- 2000-11-30 DE DE60010921T patent/DE60010921T3/de not_active Expired - Lifetime
- 2000-11-30 RS YUP-375/02A patent/RS50372B/sr unknown
- 2000-11-30 AT AT00990628T patent/ATE267246T1/de active
- 2000-11-30 PL PL356390A patent/PL206816B1/pl not_active IP Right Cessation
- 2000-11-30 PT PT00990628T patent/PT1234024E/pt unknown
- 2000-11-30 EP EP04007406A patent/EP1437400A3/en not_active Withdrawn
- 2000-11-30 ES ES00990628T patent/ES2218276T5/es not_active Expired - Lifetime
- 2000-11-30 SI SI200030394T patent/SI1234024T2/sl unknown
- 2000-11-30 IL IL14985900A patent/IL149859A0/xx unknown
- 2000-11-30 WO PCT/EP2000/012063 patent/WO2001039797A2/en active IP Right Grant
- 2000-11-30 KR KR1020027007118A patent/KR100755814B1/ko not_active IP Right Cessation
- 2000-11-30 HU HU0203305A patent/HU228205B1/hu not_active IP Right Cessation
- 2000-11-30 BR BR0016145-4A patent/BR0016145A/pt not_active IP Right Cessation
- 2000-11-30 JP JP2001541529A patent/JP4637432B2/ja not_active Expired - Fee Related
- 2000-11-30 TR TR2004/01186T patent/TR200401186T4/xx unknown
- 2000-12-04 AR ARP000106406A patent/AR027893A1/es active IP Right Grant
-
2002
- 2002-05-06 ZA ZA200203560A patent/ZA200203560B/xx unknown
- 2002-05-22 NO NO20022419A patent/NO331812B1/no not_active IP Right Cessation
- 2002-05-27 IL IL149859A patent/IL149859A/en not_active IP Right Cessation
- 2002-09-11 US US10/238,786 patent/US7368557B2/en not_active Expired - Fee Related
-
2006
- 2006-08-03 AU AU2006203327A patent/AU2006203327B2/en not_active Ceased
-
2008
- 2008-09-30 US US12/285,213 patent/US20100167352A1/en not_active Abandoned
-
2010
- 2010-11-03 US US12/938,771 patent/US20110142879A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU785081B2 (en) | Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant RNA-virus | |
EP1792996A1 (en) | Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV) | |
EP1736539A1 (en) | Attenuated SARS-CoV vaccines | |
NZ529691A (en) | Coronaviruses and diagnosis, therapeutic use and vaccines derived thereof. | |
AU729044B2 (en) | Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines | |
US20060171962A1 (en) | SARS vaccine | |
EP1632247A1 (en) | Nucleic acid sequences encoding FMDV proteins capable of associating into a virus-like particle | |
ENJUANES SANCHEZ | Patent 2393325 Summary | |
US7279327B2 (en) | Methods for producing recombinant coronavirus | |
EP4436596A1 (en) | Coronavirus derived rna replicons and their use as vaccines | |
US20050152920A1 (en) | Nucleic acid sequence comprising the rna packaging signal of a group 1 coronavirus and the applications thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB9A | Suspension of patent application procedure |